In-silico drug repurposing for targeting SARS-CoV-2 main protease (Mpro)

被引：36

作者：

Sharma, Shilpa ^{[1
]}

Deep, Shashank ^{[1
]}

机构：

[1] Indian Inst Technol Delhi, Dept Chem, New Delhi 110016, India

来源：

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS | 2022年 / 40卷 / 07期

关键词：

COVID-19; SARS-CoV-2; MD simulation; repurposing; EGCG; GREEN TEA; EPIGALLOCATECHIN GALLATE; INFECTION; DISCOVERY; COVID-19;

D O I：

10.1080/07391102.2020.1844058

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

COVID-19, caused by novel coronavirus or SARS-CoV-2, is a viral disease which has infected millions worldwide. Considering the urgent need of the drug for fighting against this infectious disease, we have performed in-silico drug repurposing followed by molecular dynamics (MD) simulation and MM-GBSA calculation. The main protease (M-pro) is one of the best-characterized drug targets among coronaviruses, therefore, this was screened for already known FDA approved drugs and some natural compounds. Comparison of docking and MD simulation results of complexes of drugs with that of inhibitor N3 (experimentally obtained) suggests EGCG, withaferin, dolutegravir, artesunate as potential inhibitors of the main protease (M-pro). Further, in silico docking and MD simulation suggest that EGCG analogues ZINC21992196 and ZINC 169337541 may act as a better inhibitor. Communicated by Ramaswamy H. Sarma

引用

页码：3003 / 3010

页数：8

共 50 条

[21] In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins
Maffucci, Irene
Contini, Alessandro
[J]. JOURNAL OF PROTEOME RESEARCH, 2020, 19 (11) : 4637 - 4648
[22] Targeting two potential sites of SARS-CoV-2 main protease through computational drug repurposing
Prakash, Archisha
Borkotoky, Subhomoi
Dubey, Vikash Kumar
[J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (07): : 3014 - 3024
[23] In silico approach identified benzoylguanidines as SARS-CoV-2 main protease (Mpro) potential inhibitors
de Santiago-Silva, Kaio Maciel
Camargo, Priscila
da Silva Gomes, Gabriel Felix
Sotero, Ana Paula
Orsato, Alexandre
Perez, Carla Cristina
Nakazato, Gerson
da Silva Lima, Camilo Henrique
Bispo, Marcelle
[J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (16): : 7686 - 7699
[24] Protegrin-2, a potential inhibitor for targeting SARS-CoV-2 main protease Mpro
Jan, Zainab
Geethakumari, Anupriya M.
Biswas, Kabir H.
Jithesh, Puthen Veettil
[J]. COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2023, 21 : 3665 - 3671
[25] Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors
Fiorucci, Diego
Milletti, Eva
Orofino, Francesco
Brizzi, Antonella
Mugnaini, Claudia
Corelli, Federico
[J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021, 39 (16): : 6242 - 6248
[26] Repurposing of antimycobacterium drugs for COVID-19 treatment by targeting SARS CoV-2 main protease: An in-silico perspective
Chakraborty, Ayon
Ghosh, Rajesh
Mohapatra, Saswati Soumya
Barik, Subhashree
Biswas, Ashis
Chowdhuri, Snehasis
[J]. GENE, 2024, 922
[27] SARS-CoV-2 main protease targeting potent fluorescent inhibitors: Repurposing thioxanthones
Batibay, Gonul S.
Metin, Eyup
[J]. TURKISH JOURNAL OF CHEMISTRY, 2023, 47 (02) : 329 - 345
[28] Reprofiling of approved drugs against SARS-CoV-2 main protease: an in-silico study
Kumar, Prateek
Bhardwaj, Taniya
Kumar, Ankur
Gehi, Bhuvaneshwari R.
Kapuganti, Shivani K.
Garg, Neha
Nath, Gopal
Giri, Rajanish
[J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (07): : 3170 - 3184
[29] An in-silico evaluation of dietary components for structural inhibition of SARS-Cov-2 main protease
Pandey, Anand Kumar
Verma, Shalja
[J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (01): : 136 - 142
[30] Apigenin analogues as SARS-CoV-2 main protease inhibitors: In-silico screening approach
Farhat, Ameny
Ben Hlima, Hajer
Khemakhem, Bassem
Ben Halima, Youssef
Michaud, Philippe
Abdelkafi, Slim
Fendri, Imen
[J]. BIOENGINEERED, 2022, 13 (02) : 3350 - 3361

← 1 2 3 4 5 →